Salim Syed
Stock Analyst at Mizuho
(1.94)
# 2,930
Out of 4,784 analysts
76
Total ratings
34.43%
Success rate
-6.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $8.62 | +155.22% | 5 | Nov 21, 2024 | |
| NKTX Nkarta | Maintains: Outperform | $20 → $16 | $2.00 | +700.00% | 7 | Nov 21, 2024 | |
| GILD Gilead Sciences | Maintains: Outperform | $90 → $100 | $111.79 | -10.55% | 6 | Nov 21, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $99 → $103 | $43.19 | +138.48% | 6 | Nov 21, 2024 | |
| BIIB Biogen | Maintains: Outperform | $251 → $207 | $138.37 | +49.60% | 15 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $69.46 | +134.67% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $6.53 | +175.65% | 4 | Aug 16, 2024 | |
| AMGN Amgen | Maintains: Neutral | $223 → $235 | $306.95 | -23.44% | 7 | May 9, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $21.07 | +61.37% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $36.99 | +167.64% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $35.11 | +50.95% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $1.14 | +426.32% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $0.84 | +2,404.17% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $10.62 | +238.98% | 1 | Nov 16, 2022 |
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $8.62
Upside: +155.22%
Nkarta
Nov 21, 2024
Maintains: Outperform
Price Target: $20 → $16
Current: $2.00
Upside: +700.00%
Gilead Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $90 → $100
Current: $111.79
Upside: -10.55%
Cytokinetics
Nov 21, 2024
Maintains: Outperform
Price Target: $99 → $103
Current: $43.19
Upside: +138.48%
Biogen
Nov 21, 2024
Maintains: Outperform
Price Target: $251 → $207
Current: $138.37
Upside: +49.60%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $69.46
Upside: +134.67%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $6.53
Upside: +175.65%
Amgen
May 9, 2024
Maintains: Neutral
Price Target: $223 → $235
Current: $306.95
Upside: -23.44%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $21.07
Upside: +61.37%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $36.99
Upside: +167.64%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $35.11
Upside: +50.95%
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $1.14
Upside: +426.32%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $0.84
Upside: +2,404.17%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $10.62
Upside: +238.98%